Janux Therapeutics, Inc. (NASDAQ: JANX) is a Healthcare company (Biotechnology) with a market capitalization of $655M. The Maz Rating grades it against the other companies in its sector.
Janux Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $10.71, Janux Therapeutics, Inc. trades at 28.1x sales and 0.7x book value. Over the last twelve months it generated about $23M of revenue and a net loss of $98M. It runs an operating margin of -599.3% and a net margin of -428.7%. It shows return on equity of -10.7%, return on invested capital of -15.0% and a free cash flow yield of -8.3%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 17.69. Over the past 52 weeks the share price ranged from $10.50 to $35.34, with a beta of 2.39.
Janux Therapeutics, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 12 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Janux Therapeutics, Inc. (JANX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 88.8% / 30% · Interest income / Revenue 104.3% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 88.8% / 33% · Receivables / Mkt Cap (36m) 0.62% / 49% · Interest income / Revenue 104.3% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 88.8% / 33.33% · Receivables / Mkt Cap (24m) 0.62% / 33.33% · Interest income / Revenue 104.3% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 95.5% / 33.33% · Receivables / Avg Assets (4Q) 1.54% / 33.33% · Interest income / Revenue 104.3% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 96.1% / 33.33% · (Cash+Recv) / Total Assets 96.8% / 33.33% · Interest income / Revenue 104.3% / 5% | Fail |
No. As of September 2026, Janux Therapeutics, Inc. (JANX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Janux Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 104.3% of each dividend: Janux Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.